Under one in 10 patients eligible to benefit from weight-loss injections like Wegovy are able to get them, warns the WHO as it publishes its initial advice on the therapies.
Considering over a billion individuals worldwide now obese, it is calling for more widespread and fairer access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"The new guidelines recognises that obesity is a long-term condition that can be treated with thorough and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key barriers to universal access to the treatments that can assist patients in reducing significant body mass, says the body.
Skinny Jab Supply Crisis
Even in the current most favorable case, the manufacturing of such drugs might only reach approximately 100 million people – fewer than 10% of those who need them, according to the health organization.
The recommendation urges nations and manufacturers to widen access, through measures like licensing agreements.
Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is due to expire in several nations in 2026.
How Weight-Loss Jabs Function
These medications replicate a biological compound to delay gastric emptying, reduce hunger and increase the sense of being full so people eat less.
People typically start to lose weight within a few weeks of commencing the regular doses.
Research suggests patients may put most of the weight back on within a year of discontinuing the drug, because their typical hunger return.
Being overweight or obese elevates your chance for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight impacts individuals in countries worldwide and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
